Transcenta Holding Limited (HKG:6628)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.320
+0.230 (11.00%)
At close: Mar 10, 2026
29.61%
Market Cap 1.04B
Revenue (ttm) 10.31M
Net Income (ttm) -291.87M
Shares Out 449.89M
EPS (ttm) -0.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,172,280
Average Volume 1,013,479
Open 2.090
Previous Close 2.090
Day's Range 2.090 - 2.340
52-Week Range 0.990 - 5.800
Beta -0.18
RSI 52.41
Earnings Date Mar 27, 2026

About Transcenta Holding

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People’s Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric and gastroesophageal cancer; TST808, a humanized antibody regulating B/plasma cell; TST005, a PD-L1/TGF-β b... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 171
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6628
Full Company Profile

Financial Performance

In 2024, Transcenta Holding's revenue was 11.26 million, a decrease of -79.09% compared to the previous year's 53.85 million. Losses were -290.29 million, -37.24% less than in 2023.

Financial numbers in CNY Financial Statements

News

Transcenta Collaborates With EirGenix To License HiCB Platform

(RTTNews) - Transcenta Holding Limited (6628.HK) announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc., a global biopharmaceutical developmen...

2 months ago - Nasdaq